The 13 most recent market catalysts affecting $CRBP, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 14, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Raises Crescent Biopharma Price Target to $40
HC Wainwright & Co. announced an increase in its price target for Crescent Biopharma, Inc. to $40.00 per share from $36.00. This analyst upgrade reflects a more favorable view of t…
Nov 13, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Adjusts Price Target on Crescent Biopharma to $31
Wedbush Securities has raised its price target for Crescent Biopharma from $27 to $31, while reiterating its Outperform rating. This move signals increased confidence from the anal…
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 55
Mizuho Lowers Price Target on Corbus Pharmaceuticals to $23
Mizuho Securities analyst Graig Suvannavejh lowered the price target for Corbus Pharmaceuticals (CRBP) from $24 to $23, while keeping an 'Outperform' rating. This adjustment is a r…
Nov 10, 2026
Corporate Catalyst
Neutral
Impact 75
Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals reported a net loss of $37.8 million for Q3 2026, significantly wider than the $23.3 million loss in Q3 2025. This increase was primarily driven by a $15.0 m…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 85
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'
Corbus Pharmaceuticals announced positive topline results from its CANYON-1 Phase 1b trial for CRB-913, an oral obesity treatment. The drug demonstrated robust weight loss across a…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 92
Corbus Pharma Announces Topline Data From CANYON-1 Phase 1b Trial Of CRB-913 Demonstrating Statistically Significant And Clinically Meaningful Weight Loss In Obesity
Corbus Pharmaceuticals announced positive topline data from its Phase 1b trial for CRB-913, an oral, non-incretin obesity medicine. The drug demonstrated statistically significant …
Sep 11, 2026
Corporate Catalyst
Bullish
Impact 85
Corbus Pharmaceuticals Holdings shares are trading higher after the company announced it will host a conference call webcast on September 14 to discuss topline data for CANYON-1.
The announcement of a conference call to discuss topline data for a clinical trial is a significant corporate catalyst for a biotechnology company. Positive data could lead to a su…
Sep 11, 2026
Corporate Catalyst
Neutral
Impact 85
Corbus Pharmaceuticals To Report Topline CANYON-1 Obesity Trial Data For CRB-913; Management Team Will Host A Conference Call Webcast On Monday, September 14 At 8:00 a.m. EDT
Corbus Pharmaceuticals is announcing the upcoming release of topline data for its Phase 1b CANYON-1 obesity trial for CRB-913. This is a critical juncture for the company as the da…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48
Oppenheimer analyst Jeff Jones maintained an 'Outperform' rating on Corbus Pharmaceuticals (CRBP), signaling continued confidence in the company's long-term prospects. However, the…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate
Corbus Pharmaceuticals (CRBP) announced Q2 EPS of $(1.81), missing analyst estimates of $(1.26) by a substantial 43.65%. This significant earnings miss is a major negative catalyst…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 55
Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity
Corbus Pharmaceuticals announced a procedural milestone in its CANYON-1 Phase 1b clinical trial for CRB-913, an obesity drug, with the last patient completing their final visit. Th…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 75
Corbus Pharmaceuticals Receives FDA Clearance To Start Its TEMPO-1 Registrational StudyOf CRB-701, A Nectin-4 Targeted Antibody Drug Conjugate In Second-Line Oropharyngeal Squamous Cell Carcinoma
The FDA clearance for a registrational study is a critical milestone for any pharmaceutical company, particularly for a smaller biotech like Corbus. It indicates that the FDA sees …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.